[Systemic approach to investigation of levitra efficacy in patients with chronic prostatitis with erectile dysfunction].
Ultrasonic dopplerography of prostatic, scrotal and penile vessels before and after intake of levitra in a dose 10 mg was made in 22 patients with chronic abacterial prostatitis in combination with erectile dysfunction and after their combined levitra treatment for a month taken each other day. It was found that levitra accelerates arterial inflow to the prostatic gland, testicles and penis (even in the absence of sexual stimulation and erection). This evidence indicates a distinct vasculogenic effect of levitra on male genitalia. Thus, levitra is a promising drug in the treatment of chronic prostatitis, excretory infertility. It is recommended to take levitra regularly 2-3 times a week to manage vascular genital disorders.
Aliaev
Iu G
IuG
Ronkin
M A
MA
Esilevskiĭ
Iu M
IuM
Zhuchenko
T D
TD
Demidko
Iu L
IuL
Krupinov
G E
GE
Shcherbanina
V Iu
VIu
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D002560:Cerebrovascular Circulation / Q000187:drug effects; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004334:Drug Administration Schedule; D007172:Erectile Dysfunction / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010413:Penis / Q000098:blood supply / Q000187:drug effects / Q000201:enzymology; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011467:Prostate / Q000098:blood supply / Q000187:drug effects / Q000201:enzymology; D011472:Prostatitis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012039:Regional Blood Flow / Q000187:drug effects; D013450:Sulfones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013737:Testis / Q000098:blood supply / Q000187:drug effects / Q000201:enzymology; D016896:Treatment Outcome; D014227:Triazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069058:Vardenafil Dihydrochloride
D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human